My Top 5 Favorite Stocks for an Uncertain Market

Source The Motley Fool

Key Points

  • These companies offer essential products or medicines, or have qualities that favor resilience during tough times.

  • And you may benefit from these stocks during strong market times too, making them fantastic long-term investments.

  • 10 stocks we like better than Johnson & Johnson ›

The S&P 500 has climbed this year, adding to three consecutive years of gains. But with levels near record highs, valuations relatively high, and concerns about artificial intelligence (AI) spending and rising inflation brewing, some investors have become more cautious. That's why right now is an excellent time to add a few highly resilient stocks to your portfolio.

These players have what it takes to maintain a certain level of stability or even excel during any market environment. They are providers of essential medicines, sellers of items we need daily, or offer another feature that helps them keep business rolling in easy times and tough times. So, if today's headwinds weigh further on the market, such stocks will offer you security; but if troubles blow over, these stocks still make great long-term investments.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Let's check out my five favorite stocks to buy during uncertain market times.

An investor points to something on a computer screen to show another investor.

Image source: Getty Images.

1. Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) sells some of the most successful pharmaceutical and medtech products around -- in fact, it has 28 products and platforms that generate more than $1 billion in annual revenue. This puts the company on track to reach a major goal this year: $100 billion in sales.

This healthcare giant has been delivering growth in both its innovative medicine (pharma) and medtech businesses quarter after quarter, and it has demonstrated that it can grow significantly even after losing exclusivity on a star product -- that's immunology drug, Stelara. In the recent quarter, eight J&J innovative medicine brands delivered double-digit sales gains.

Meanwhile, J&J is a Dividend King, meaning it's increased its dividend payments for more than 50 consecutive years. So you can count on this company for passive income, no matter what the stock market is doing.

2. Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ:VRTX) is the leader in the cystic fibrosis (CF) treatment market, with intellectual property ensuring its position until the late 2030s. These products helped the company deliver $12 billion in revenue last year.

On top of this, Vertex has taken impressive steps into other treatment areas, winning approval in recent years for a pain drug and a gene editing treatment for blood disorders. These two products, being rather new, have plenty of room for growth. And Vertex's pipeline, with a fresh focus on renal conditions, offers another potential catalyst for sales gains down the road. The company submitted povetacicept for adults with immunoglobulin A nephropathy to regulators for potential approval and awaits a decision by late November.

All of this makes now a fantastic time to get in on this innovative biotech player.

3. Costco

Costco (NASDAQ:COST) offers customers access to essentials like groceries and gas for dirt cheap prices, and this is something that's particularly attractive when times are tough. Though customers pay an annual fee to shop in Costco's warehouses, the savings may more than compensate. And the high membership renewal rate -- greater than 90% in the U.S. and Canada -- suggests customers see value in shopping here.

All of this means Costco is likely to see strength even during uncertain times. I also like the fact that the company makes most of its profit from membership fees, so it's generating revenue before shoppers even set foot in the door. This, along with the high renewal rates, also offers investors a certain level of visibility on sales to come.

You can count on Costco for dividends, and the company has even paid special dividends in the past -- the most recent was a $15 per share payment in 2024.

Hand filling a red paper cup with fizzy soda from a self-serve fountain drink machine

Image source: Getty Images.

4. Coca-Cola

Coca-Cola's (NYSE:KO) eponymous beverage may not be an absolutely necessary product, but the company offers a broad range of non-alcoholic drinks in essentials such as water, juices, and coffee. And the company's brand strength means that even its sparkling beverages can hold their own during challenging economic times.

The drinks giant also has shown itself to be adaptable over time, creating beverages tailored to the needs of specific markets. All of this has helped Coca-Cola to continually gain value share and grow earnings over time.

Coca-Cola is also a Dividend King, meaning it’s shown its commitment to rewarding investors, too. Its high level of free cash flow, at about $14 billion, suggests it has what it takes to keep this momentum going. So investors can count on Coca-Cola for earnings strength and passive income.

5. American Express

American Express (NYSE:AXP) is a payment card powerhouse, and you might think that this would be a point of weakness in tough times. But American Express' customers tend to be affluent, and this population is less sensitive to economic shifts. This has offered the company earnings stability even during downturns.

I also like the idea that American Express continues to win over younger populations, suggesting that the payment card company may see growth in the years to come. In the most recent quarter, for example, 65% of global new consumer accounts were from Millennials and Gen Z.

"We continued to attract a large number of new customers, particularly Millennials and Gen-Zs who represent greater lifetime value," the company said in its report.

And like some of the other stocks I've mentioned here, American Express offers investors dividend growth, making it a fantastic stock to buy for an uncertain market.

Should you buy stock in Johnson & Johnson right now?

Before you buy stock in Johnson & Johnson, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $433,160!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,254!*

Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of September 16, 2026.

American Express is an advertising partner of Motley Fool Money. Adria Cimino has positions in American Express and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends American Express, Costco Wholesale, and Vertex Pharmaceuticals. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Brent tests $108 as a key export pipeline stays shut — can the rally clear $110?Brent crude rose 2.55% to $106.97 and WTI 2.32% to $102.30 as a major regional export pipeline remained offline with no restart timeline. Front-month backwardation has widened to $5.53 from $3.84 a week ago, European gas is at its highest since December 2022, and one analyst sees $119.48 if talks stall.
Author  Irene Q.
Sep 14, Mon
Brent crude rose 2.55% to $106.97 and WTI 2.32% to $102.30 as a major regional export pipeline remained offline with no restart timeline. Front-month backwardation has widened to $5.53 from $3.84 a week ago, European gas is at its highest since December 2022, and one analyst sees $119.48 if talks stall.
placeholder
Fed hike odds near 90% into Wednesday's decision — how to trade the dollar, gold and the S&P 500A 0.3% monthly core CPI print has lifted the market-implied probability of a 25bp Fed hike on 16 September to roughly 86.5% ~ 90%, which would be the first increase since July 2023. Here is the decision timeline, the pricing versus the forecasts, both scenarios, and the key levels for the dollar, gold and the S&P 500.
Author  Suzie
Sep 14, Mon
A 0.3% monthly core CPI print has lifted the market-implied probability of a 25bp Fed hike on 16 September to roughly 86.5% ~ 90%, which would be the first increase since July 2023. Here is the decision timeline, the pricing versus the forecasts, both scenarios, and the key levels for the dollar, gold and the S&P 500.
placeholder
Gold falls below $4,300 as higher US yields bolster Fed rate hike betsGold price (XAU/USD) tumbles to near $4,295 during the early Asian session on Tuesday. The precious metal faces some selling pressure as rising bond yields and surging energy prices strengthen expectations that the US Federal Reserve (Fed) will raise interest rates this week. 
Author  FXStreet
Yesterday 01: 23
Gold price (XAU/USD) tumbles to near $4,295 during the early Asian session on Tuesday. The precious metal faces some selling pressure as rising bond yields and surging energy prices strengthen expectations that the US Federal Reserve (Fed) will raise interest rates this week. 
placeholder
【Daily Brief】10-year Treasury yield briefly tops 5%, S&P 500 slips to 7,602 and the dollar firms at 99.3 as the Fed's decision eve beginsThe 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.
Author  Irene Q.
Yesterday 08: 16
The 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.
placeholder
Silver breaks $64 as precious metals rebound — can gold hold the $4,280 line into the Fed decision?Silver has climbed back above $64 an ounce for the first time this week, leading a broad rebound across precious metals hours before the Federal Reserve delivers what is expected to be its first rate hike since 2023. Spot silver was last at $64.64, up 1.49% on the day, while gold reclaimed $4,300 and platinum and palladium both advanced. The question now is whether the bounce is a genuine turn — or a pause before the Fed's dot plot decides the next move.
Author  Suzie
4 hours ago
Silver has climbed back above $64 an ounce for the first time this week, leading a broad rebound across precious metals hours before the Federal Reserve delivers what is expected to be its first rate hike since 2023. Spot silver was last at $64.64, up 1.49% on the day, while gold reclaimed $4,300 and platinum and palladium both advanced. The question now is whether the bounce is a genuine turn — or a pause before the Fed's dot plot decides the next move.
goTop
quote